RaQualia Pharma Inc. (TYO:4579)
Japan flag Japan · Delayed Price · Currency is JPY
720.00
-23.00 (-3.10%)
Nov 18, 2026, 10:20 AM JST

RaQualia Pharma Statistics

Total Valuation

RaQualia Pharma has a market cap or net worth of JPY 18.74 billion. The enterprise value is 16.46 billion.

Market Cap18.74B
Enterprise Value 16.46B

Important Dates

The last earnings date was Friday, November 13, 2026.

Earnings Date Nov 13, 2026
Ex-Dividend Date n/a

Share Statistics

RaQualia Pharma has 26.03 million shares outstanding. The number of shares has increased by 12.57% in one year.

Current Share Class 26.03M
Shares Outstanding 26.03M
Shares Change (YoY) +12.57%
Shares Change (QoQ) +0.01%
Owned by Insiders (%) 11.87%
Owned by Institutions (%) -3.18%
Float 17.57M

Valuation Ratios

The trailing PE ratio is 53.36.

PE Ratio 53.36
Forward PE n/a
PS Ratio 4.81
PB Ratio 2.48
P/TBV Ratio 4.52
P/FCF Ratio 41.95
P/OCF Ratio 38.61
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 16.12, with an EV/FCF ratio of 37.00.

EV / Earnings 48.88
EV / Sales 4.25
EV / EBITDA 16.12
EV / EBIT 28.98
EV / FCF 37.00

Financial Position

The company has a current ratio of 6.29, with a Debt / Equity ratio of 0.33.

Current Ratio 6.29
Quick Ratio 5.62
Debt / Equity 0.33
Debt / EBITDA 2.39
Debt / FCF 5.49
Interest Coverage 9.49

Financial Efficiency

Return on equity (ROE) is 5.05% and return on invested capital (ROIC) is 6.03%.

Return on Equity (ROE) 5.05%
Return on Assets (ROA) 3.64%
Return on Invested Capital (ROIC) 6.03%
Return on Capital Employed (ROCE) 6.04%
Weighted Average Cost of Capital (WACC) 8.04%
Revenue Per Employee 47.27M
Profits Per Employee 4.11M
Employee Count85
Asset Turnover 0.40
Inventory Turnover 3.68

Taxes

In the past 12 months, RaQualia Pharma has paid 252.68 million in taxes.

Income Tax 252.68M
Effective Tax Rate 42.00%

Stock Price Statistics

The stock price has increased by +37.34% in the last 52 weeks. The beta is 0.85, so RaQualia Pharma's price volatility has been lower than the market average.

Beta (5Y) 0.85
52-Week Price Change +37.34%
50-Day Moving Average 614.06
200-Day Moving Average 675.56
Relative Strength Index (RSI) 66.71
Average Volume (20 Days) 294,645

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, RaQualia Pharma had revenue of JPY 4.02 billion and earned 348.98 million in profits. Earnings per share was 13.49.

Revenue4.02B
Gross Profit 3.37B
Operating Income 588.75M
Pretax Income 601.66M
Net Income 348.98M
EBITDA 1.06B
EBIT 588.75M
Earnings Per Share (EPS) 13.49
Full Income Statement

Balance Sheet

The company has 4.81 billion in cash and 2.53 billion in debt, with a net cash position of 2.28 billion or 87.66 per share.

Cash & Cash Equivalents 4.81B
Total Debt 2.53B
Net Cash 2.28B
Net Cash Per Share 87.66
Equity (Book Value) 7.79B
Book Value Per Share 299.22
Working Capital 5.07B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 501.00 million and capital expenditures -40.00 million, giving a free cash flow of 461.00 million.

Operating Cash Flow 501.00M
Capital Expenditures -40.00M
Depreciation & Amortization 469.71M
Net Borrowing -512.00M
Free Cash Flow 461.00M
FCF Per Share 17.71
Full Cash Flow Statement

Margins

Gross margin is 83.93%, with operating and profit margins of 14.65% and 8.69%.

Gross Margin 83.93%
Operating Margin 14.65%
Pretax Margin 14.97%
Profit Margin 8.69%
EBITDA Margin 26.34%
EBIT Margin 14.65%
FCF Margin 11.82%

Dividends & Yields

RaQualia Pharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -12.57%
Shareholder Yield -12.57%
Earnings Yield 1.87%
FCF Yield 2.38%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside
Graham Formula Value
Graham Formula Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

RaQualia Pharma has an Altman Z-Score of 4.9 and a Piotroski F-Score of 8.

Altman Z-Score 4.9
Piotroski F-Score 8